Rutkowski P, Slominska EM, Wołyniec W, Smoleński RT, Szolkiewicz M, Swierczyński J, et al. Nicotinamide metabolites accumulate in the tissues of uremic rats. J Ren Nutr. 2008;18:56–9.PubMedCrossRef 38. Gillmor HA, Bolton CH, Hopton M, Moore WP, Perrett D, Bingley PJ, et al. Measurement of nicotinamide and N-methyl-2-pyridone-5-carboxamide in plasma by high performance liquid chromatography.

Biomed Chromatogr. 1999;13:360–2.PubMedCrossRef 39. Rutkowski B, Slominska E, Szolkiewicz M, Smolenski RT, Striley C, Rutkowski P, et al. N-methyl-2-pyridone-5-carboxamide: a novel uremic toxin? Kidney Int Suppl. 2003;(84):S19–21. 40. Slominska EM, Kowalik K, Smolenski RT, Szolkiewicz M, Rutkowski P, Rutkowski B, et al. Accumulation of poly(ADP-ribose) polymerase inhibitors in children with chronic renal failure. Pediatr Nephrol. 2006;21:800–6.PubMedCrossRef 41. Rutkowski B, Rutkowski P, Słomińska E, Smolenski RT, Swierczyński J. Cellular ARN-509 clinical trial toxicity of nicotinamide metabolites. J Ren Nutr. 2012;22:95–7.PubMedCrossRef 42. Knip M, Douek IF, Moore WPT, Gillmor HA, McLean AEM, Bingley PJ, et al. Safety of high-dose nicotinamide: a review. Diabetologia. 2000;43:1337–45.PubMedCrossRef 43. CRT0066101 Beyer KH, Russo HF. Renal tubular elimination of N1-methylnicotinamide. Am J Physiol. 1950;160:311–20.PubMed 44. Sampathkumar K, Selvam M, Sooraj YS, Gowthaman S, Ajeshkumar RNP. Extended release nicotinic acid—a novel oral agent for phosphate control. Int

Urol Nephrol. 2006;38:171–4.PubMedCrossRef 45. Müller D, Mehling H, Otto B, Bergmann-Lips R, Luft F, Jordan J, et al. Niacin lowers serum phosphate and increases HDL cholesterol in dialysis patients. Clin J Am Soc Nephrol. 2007;2:1249–54.PubMedCrossRef 46. Restrepo Valencia CA, Cruz J. Safety and effectiveness of nicotinic acid in the management of patients

with chronic renal disease and hyperlipidemia associated to hyperphosphatemia. Nefrologia. 2008;28:61–6. 47. Maccubbin D, Tipping D, Kuznetsova O, Hanlon WA, Bostom AG. Hypophosphatemic effect of niacin in patients without renal failure: a Resveratrol randomized trial. Clin J Am Soc Nephrol. 2010;5:582–9.PubMedCrossRef 48. Takahashi Y, selleck kinase inhibitor Tanaka A, Nakamura T, Fukuwatari T, Shibata K, Shimada N, et al. Nicotinamide suppresses hyperphosphatemia in hemodialysis patients. Kidney Int. 2004;65:1099–104.PubMedCrossRef 49. Cheng SC, Young DO, Huang Y, Delmez JA, Coyne DW. A randomized, double-blind, placebo-controlled trial of niacinamide for reduction of phosphorus in hemodialysis patients. Clin J Am Soc Nephrol. 2008;3:1131–8.PubMedCrossRef 50. Young DO, Cheng SC, Delmez JA, Coyne DW. The effect of oral niacinamide on plasma phosphorus levels in peritoneal dialysis patients. Perit Dial Int. 2009;29:562–7.PubMed 51. Shahbazian H, Zafar Mohtashami A, Ghorbani A, Abbaspour MR, Belladi Musavi SS, Hayati F, et al. Oral nicotinamide reduces serum phosphorus, increases HDL, and induces thrombocytopenia in hemodialysis patients: a double-blind randomized clinical trial. Nefrologia. 2011;31:58–65. 52.